Addition of cetuximab to cisplatin doubled response in metastatic breast cancer

  • June 19, 2013

The addition of cetuximab to cisplatin doubled the overall response rate and prolonged OS compared with cisplatin alone in patients with metastatic triple-negative breast cancer, according to results of a randomized phase 2 study.

However, the combination treatment did not meet the predetermined response rate of more than 20%.

Full Story »
  • Filter By:

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
  • HemOncToday Blog
  • William Wood, MD
  • Contending with ‘Dr.’ Google
  • How active are your patients in consulting “Dr. Google” — and how do you think this process might become more effective, and more safe?
More»
More »
[X]